ROC analysis was used to assess the validity of SVIL mRNA expression levels in differentiating bladder cancer from normal tissues with an estimated AUC of 0.757 (95% CI 0.626–0.887) in the TCGA-BLCA dataset (Fig. 4A), and in the GSE13507 dataset to assess the expression of SVIL to differentiate bladder cancer tissues from normal tissues in the GSE13507 dataset, the AUC of SVIL was 0.698 (95% CI 0.626–0.769, Fig. 4B). This evidence concerns the gene SVIL and urinary bladder carcinoma.